Michael Sension

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antonella Castagna, Franco Maggiolo, Giovanni Penco et al. · The Journal of Infectious Diseases · 2014 · 329 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV

Kathleen Squires, Adriano Lazzarin, Jos M. Gatell et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2004 · 299 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy

Calvin Cohen, Susan C. Hunt, Michael Sension et al. · AIDS · 2002 · 197 citations

Life Sciences, Pharmacotherapy, Hiv Control +16

Improvement in Lipoatrophy Associated with Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus–Infected Patients Switched from Stavudine to Abacavir or Zidovudine: The Results of the TARHEEL Study

Grace A. McComsey, Douglas Ward, Siegrid M. Hessenthaler et al. · Clinical Infectious Diseases · 2004 · 187 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Long-Term Efficacy and Safety of Atazanavir With Stavudine and Lamivudine in Patients Previously Treated With Nelfinavir or Atazanavir

Robin Wood, Praphan Phanuphak, Pedro Cahn et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2004 · 102 citations

Pharmacy, Pharmacology, Pharmacotherapy +17